Pfizer Inc. (PFE)

All Comments on PFE

  • commenter
    SmallCapBioI
    nvestor
    Aug 17 07:08 PM
    5 Potential Buyout Targets in Biotech - Barron's [view article]
    There are many small and microcap medical companies that many of these large pharmas could buy without sneezing. One is DCTH which could bring new life to drugs new and old. Reply
  • commenter
    nova
    Aug 17 05:35 PM
    My Website
    5 Potential Buyout Targets in Biotech - Barron's [view article]
    Unfortunately, American Big Pharma companies became more marketing organizations rather than new drug development companies.

    It appears that, at the time when companies like ImClone are developing new super-drugs like Erbitux capable of savings thousands of lives, the Wall Street green-mailers, speculators, extortionists and biotech companies stock price manipulations greatly endanger new drugs development process doing great disservice to people all around world.

    The above article is discussing how Big Pharma, with their zillion-dollars executives compensation packages, has failed in development of drugs and now is in a process of ripping off the most innovative and successful biotech companies and its shareholders.

    These Big Pharma acquisition activities add nothing to new drug development but greatly endanger so many lives that could be saved by new drugs.

    Reply
  • commenter
    in4thelongha
    ul
    Aug 17 02:13 PM
    5 Potential Buyout Targets in Biotech - Barron's [view article]
    I would add to that list BIIB...considering the absurd sh/pr hit which Biogen has taken on Tysabri and the fact that Carl Icahn is accumulating. ELN is of course caught up in the same recent events and is also a prime target for acquisition by either Wyeth (WYE) or Biogen Idec (BIIB).

    Add Dendreon (DNDN) to the list if their interim analysis of Provenge (October estimate) for end-stage prostate cancer is sufficiently positive to allow for immediate trial cessation and refiling of BLA...I would give them roughly a 75% chance of sufficient success at the interim btw.     Reply
  • commenter
    PrudentMan
    Aug 17 11:22 AM
    5 Potential Buyout Targets in Biotech - Barron's [view article]
    The patent expiration problems of large pharma are well know. This article would have added value if the specific reasons why the target companies were potential takeovers would have given substance to it.

    In this day where primary research is virtually missing and everyone seems to be peddling their portfolio, it would be refreshing to get sound reasoning backed by substantive facts rather than mere opinions which are worth exactly what you pay for them.     Reply
  • commenter
    Richard
    Wendling
    Aug 16 07:56 AM
    My Website
    Dow 30 Trading Ranges [view article]
    What is more important than listing trading ranges on these Dow components is listing the number of those Dow components that are being manipulated by their individual specialists for their own personal profits. Alcoa's specialist for example has set his issue up for a major decline in price in the coming two months.

    For more information on how this is done click on my web page and read the stock reports on AA and also read the documentation on how these individuals manipulate their issues at the expense of the investor. You have nothing to lose except the amount of time it takes you to read the information and you have a great deal to gain if you follow what they are doing and buy when they buy and sell when they sell.

    Richard     Reply
  • commenter
    Shiv
    Aug 14 07:16 AM
    Are Big Pharma's Dollar Days Nearly Over? [view article]
    I was born immortal and so shall I die; at birth I drew my first breath on a genetic memory; my heart beat of its own accord and my brain operated a highly complex organism without instruction. As I die, my genetic legacy shall live on. Humans have such a desire to live in perpetuity, be it through life extensions or reincarnations; that an industry which tries to satisfy the human quest for immortality must succeed. That aside, I have always wondered whether an answer to the age old Indian epics lies in Bio-tech; as in is immortality or reincarnation simply a genetic legacy explained; did Rama truly live for an epoch through advanced medicine or is it simply living through passage of a genetic legacy (with death being the consequence of the maternal line being ultimately extinguished); or hybrid beings (mythological beings like Garuda) a genetic possibility. There is so little we know and so much to accidentally discover; health-care remains a huge growth area. And Pfizer as an R&D focused organization has amongst the best chances of making that accidental discovery. Patience and a yield makes it worth the risk & the wait.

    Foreign sales can never be a head wind; the growth opportunities in the pharmaceutical industry lie outside US; that is where the human quest for immortality is at its earliest stage. Sure the exchange rates may imply declining revenue in $ terms; but will this happen? I think not. Overseas demand, particularly in emerging (high growth) markets where brands are favored over generics, is highly elastic. A proportionate decline in the importing country currency pricing would lead to a more than proportionate increase in demand and this could actually result in elusive growth for Pfizer. Pfizers problems are:

    (a) Science - Pfizer needs to move away from synthetics and into biologic, genetic, stem cell solutions; unlike synthetics, these latter areas are less prone to patent disputes. They can build this pipeline in house, in-license it or acquire it. More than a pipeline, I feel a high quality of earnings pipeline is what is required. Success from their existing pipeline will provide a catalyst to a higher multiple, but long term, refocus on quality of earnings needs to be a priority. Synthetics is yesterdays game and it would be a shame to see Pfizer fall by the wayside because the failed to glimpse the future; much like the US Auto majors.
    (b) Marketing - this is a big strength and it must be leveraged. With drug approvals taking so long, the time in market from patent filing is far lower than before so making the most of the market is critical.
    (c) Financial - there is limit to how much US leverage can be used for share buy backs & dividends. There is a high cash build from overseas operations and ultimately the foreign cash needs to come back to US and this will come at a tax cost. Since this cash is "trapped" outside US, perhaps use in an acquisition of non US assets would be viable. I do feel use of a debased currency such as Pfizer's shares or the $ is a deterrent in planning an acquisition, but perhaps a stronger $ will help. If this occurs, a reverse acquisition which inverts the group should be considered.
    d) Management - A visionary CEO supported by a strong General Counsel please. Patents need to be protected, but legal is a support service, not the core business.

    Overall, I believe they are headed in the right direction; but it is more of a drift than a purposeful stride. Until science delivers there is no great catalyst. Absent a catalyst, I would look for a range of $14 to $25. A catalyst emerging would drive re-rating & multiple expansion. For now, the only catalyst is the pharmaceutical industry defensive characteristics, which together with the dividend should mean the stock should find near term support and trade upwards to $25-$30range (including dividends) on a 9 month basis.

    If you consider that the stock went ex dividend, on 6 August, it is not surprising that it is a struggle to take out the $20 barrier. It also needs to systematically work through resistance at $19.91, $20.23, $20.71, 21.11 and $21.50; this is necessary for the damage of Q2's slide to be undone. If it clears $21.11 then $23 & $25 should be strong resistance levels as those were high volume sell off days which will likely mean sellers will emerge.     Reply
  • commenter
    Paxdonnaverd
    e
    Aug 13 08:49 PM
    My Website
    How Have 'Traditional Defensive Stocks' Done in This Downturn? [view article]
    Bizonly, thanks for the outlook on fast-food. I don't like the industry for personal reasons but it intrigued me how it would stay steady. Your explanation clears that up. Reply
  • commenter
    Serapis
    Aug 12 01:27 AM
    Young Jeezy's 'The Recession': I Think We’ve Bottomed Out [view article]
    I agree that the market has turned and will experience a short-run up, but I expect problems to return when we experience probably the worst holiday season in recent memory in terms of spending. Energy seems to be the defining issue of the 21st century; wars will be fought over it, nations will rise or fall based on their ability to harness it. No doubt in my mind that this is where to put the money. Energy stocks may fall in the short-term, but its clear as day their long term trend is up. Those who see this now will be much better off than those who do nothing. Reply
  • commenter
    dlaw
    Aug 11 01:26 PM
    Young Jeezy's 'The Recession': I Think We’ve Bottomed Out [view article]
    If the combination of this young fool thinking he's a contrarian because the market has been negative for five minutes and the old fool, sharksm writing "the upside over the long term is infinite", then nothing will.

    The combination of the two is the best sell signal I've ever seen.

    There is clearly WAY more optimism (or denial, take your pick) buried in the market than I thought. Until that optimism gets wrung out, we won't find post-bubble pricing.     Reply
  • commenter
    Vince
    Aug 11 10:08 AM
    My Website
    Young Jeezy's 'The Recession': I Think We’ve Bottomed Out [view article]
    Sharksm and others must realize that if they have been investing for 40 years that their "cycle" encapsulated some of the greatest market gains in history. No World Wars, unprecedented technological innovation and greater access to the markets generated a huge tailwind for you. Those tailwinds do not exist anymore. How much better than the SPX did you do over that time? My guess not much - regardless, bless you for being in their when my parents were buying penny stocks.

    Buy and hold aways works if you have the right stocks or the right market - the next twenty years will not give us the same opportunity you had. Read Shillers "Irrational Exuberance" first edition for more on those tailwinds.     Reply
  • commenter
    bizonly
    Aug 11 07:19 AM
    How Have 'Traditional Defensive Stocks' Done in This Downturn? [view article]
    in the seventies i attended a pillsbury meeting that explained that in a recession people traded down to fast food and of the top twenty things they cut- fast food was 17 -with traveling #1-

    pillsbury owned burger king at the time-all my money has been safely
    parked with bkc for over a year'turns out that meeting saved me
    over 250k     Reply
  • commenter
    investor88
    Aug 11 02:37 AM
    Young Jeezy's 'The Recession': I Think We’ve Bottomed Out [view article]
    The views of Venivi and Nordic balances out the optimistic view of Terence that the market has bottomed out. A recent article by Prieur in SeekingAlpha using US presidential election cycle analysis says a 'true bottom' of the sp500 would not appear until 2h 2010. Right now we have to observe and proceed with caution. Reply
  • commenter
    NordicImpale
    rs
    Aug 10 08:35 PM
    Young Jeezy's 'The Recession': I Think We’ve Bottomed Out [view article]
    Generally, I agree with the article-- the best statements belong to others: "... money is never made or lost – it is simply transferred from one perception to another" and, "Be greedy when others are fearful and fearful when others are greedy." The latter, is good a rule of thumb, and a mantra of the value investor, who if not careful can mistake a rational sell off for an irrational panic (Bear-Sterns). The market can ruin the experienced and the inexperienced alike, but generally rationality belongs to the experienced, and irrationality belongs to the inexperienced.

    We usually remember and apply 'past performance does not guarantee future results' to stocks and funds, but the market itself is becoming less dependable for generating wealth in the long haul. Making judgments based on historical trends in the market has become, for me, as nonsensical as comparing statistical data of any sports franchise to its own past. Market trends are less reliable today because the world is increasingly dominated by western capitalists with a global vision. They move through the world with less and less allegiance to country. Governments are bought and sold (stability of the dollar is less and less concerning to the powerful wealthy). It takes less time to build a company's business and less time to erode it. I don't know that buying and holding works like it did in the past, but it has always been true that attempting to buy at the bottom and sell at the top is rarely possible. If that is what is meant by timing the market, then I agree, it should not be attempted. But buy and hold does not pay appropriate respect to the quotes.

    So, remember the quotes, watch the P/E ratio, sector and economic growth, and stay diversified. Move incrementally in and and out of positions according to preset benchmarks, which are not necessarily automatic trades, but second guessed with high caution. As wealth increases, diversify outside the market (be sure to own some productive land).     Reply
  • commenter
    Leser
    Aug 10 06:44 PM
    Young Jeezy's 'The Recession': I Think We’ve Bottomed Out [view article]
    Nice article, Terence. The commenters on your article have points worth considering, too.
    Sharksm makes a point which harmonizes with Terence, buy and hold quality dividend stocks. Even with DRIP's one can still buy at approximate lows. Let the dividends accru until in retirement. Then have them pay out a living income--or help other retirement payments while the stocks continue growing in value.
    Wpdragon's point is valid, too, to avoid the sin stocks. Why profit on someone else's misjudgment? Suzi Ormann's mantra "people first" has much higher moral ground than Cramer's of the "I'm just here to make money" ilk. Lose that opening egotistical mantra to your show, Jim.
    By way of a positive suggestion for you Terence, when you've finished writing an article, you should read your it again after a little gestation time and ask yourself what can I weed out, what have I already expressed elsewhere in this article in other words? Your articles will be more readable if shortened.
    I think your thoughts are good.
    Thanks.


     Reply
  • commenter
    mkreisel
    Aug 10 12:40 PM
    How Have 'Traditional Defensive Stocks' Done in This Downturn? [view article]
    JNJ is at its all-time high and still dirt cheap! Reply

Trading Center


Loading...
Symbols:
Authors:
Quick Links: